Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis
- 322 Downloads
This review aims to analyse the published data on the prevalence and clinical significance of breast incidental F18-FDG uptake detected by PET or PET/CT (BIU). A comprehensive computer literature search of the PubMed/MEDLINE, Scopus and Embase databases for studies on BIU published through July 2013 was performed. Pooled prevalence and malignancy risk of BIU were calculated. The literature search revealed 42 articles, and 17 were selected. One study was excluded because of data overlap but four additional studies were found screening the references. Finally, 20 articles were included in the systematic review and 13 were eligible for a meta-analysis. The pooled prevalence of BIU on all scans was 0.4 % (95 % CI 0.23–0.61 %), the pooled prevalence on scans on female patients only was 0.82 % (95 % CI 0.51–1.2 %), the pooled risk of malignancy of BIU when further analysed was 48 % (95 % CI 38–58 %) and the pooled risk of malignancy of BIU with histological examination was 60 % (95 % CI 53–66 %). The most frequent malignant lesion detected was infiltrating ductal carcinoma. Despite being rare, the identification of BIU frequently signals the presence of an unsuspected subclinical lesion, which differs from the indicated reason for which the patient was initially scanned, and the risk of malignancy is very high.
KeywordsBreast incidental uptake FDG PET/CT Breast tumours
Conflict of interest
The authors declare no conflicts of interest.
- 1.von Karsa L, Anttila A, Ronco G, Ponti A, Malila N, Arbyn M, et al. Cancer screening in the European Union. Report on the implementation of the council recommendation on cancer screening—first report. Luxembourg: European Commission; 2008.Google Scholar
- 14.Clapp AJ, Peller PJ, Subramaniam RM. AJR teaching file: incidental breast cancer detected with F18-FDG PET/CT. Am J Roentgenol. 2011;196:WS83–85.Google Scholar
- 16.Ramani SK, Basu S, Parmar V, Gujral S, Bibte S. Second primary malignancy of breast in a patient of gastrointestinal stromal tumor presenting as fluoro-deoxyglucose-avid breast incidentaloma in fluoro-deoxyglucose-positron emission tomography. J Cancer Res Ther. 2011;7:387–9.PubMedCrossRefGoogle Scholar
- 22.Kang BJ, Lee JH, Yoo IeR, Kim SH, Choi JJ, Jeong SH, et al. Clinical significance of incidental finding of focal activity in the breast at F18-FDG PET/CT. Am J Roentgenol. 2011;197:341–347.Google Scholar
- 25.Dunne R, O’Mahony D, Wilson G, McDermott R, O’Keeffe S. The role of the breast radiologist in evaluation of breast incidentalomas detected on fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT). Br J Radiol. 2013. doi: 10.1259/bjr.20130034.
- 26.Lim S, Lee EH, Park JM, Chang YW, Kim HH, Jeong SH. Role of combined BI-RADS assessment using mammography and sonography for evaluation of incidental hypermetabolic lesions in the breast on 18F-FDG PET–CT. Acta Radiol. 2013. doi: 10.1177/0284185113492453.
- 32.National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Breast Cancer. 2011;2:BINV1–14; IBC1; M532.Google Scholar
- 38.Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labeling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25:1429–34.PubMedCrossRefGoogle Scholar